**Biomanufacturing investment** refers to capital deployed for large-scale pharmaceutical and biological production facilities. The Research Triangle has secured $18.9 billion in biomanufacturing investments announced between 2020 and 2026, creating more than 7,500 direct manufacturing jobs across 12 major facilities.
This capital deployment exceeds the total biomanufacturing investment attracted by the Boston-Cambridge cluster during the same period, marking a fundamental reallocation of pharmaceutical production capacity toward the Southeast..
Key Investments (2020-2026):
| Company | Location | Investment | Jobs |
|---|---|---|---|
| Novo Nordisk | Clayton, NC | $4.1 billion | 1,000 |
| Biogen | RTP | $2.0 billion | TBD |
| Genentech | Holly Springs | $2.0 billion | 500+ |
| Eli Lilly | Concord | $2.0 billion | 600 |
| Amgen | Holly Springs | $1.5 billion | 725 |
| Fujifilm Diosynth | Holly Springs | $1.2 billion | 680 |
| Johnson & Johnson | Wilson | $4.0 billion | 920+ |
The GLP-1 manufacturing boom—medications like Ozempic, Wegovy, Mounjaro, and Zepbound—has driven significant investment. North Carolina's life sciences industry directly employs 75,134 workers across 839 companies, generating $82.1 billion in total economic impact.
